Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 11 min ago
PreprintCC BY-NC-NDmedRxiv

Reduced egocentricity after psilocybin in patients with alcohol use disorder: a pilot randomized controlled trial

  • H. Bukowski
  • P. de Timary
  • D. Belahda
  • N. Igounenc
  • T. Mura
  • C. Serrand
  • A. Luquiens1
  1. 1CHU Nimes
Read full textPDFDOICite

Abstract

BackgroundSocial difficulties in alcohol use disorder (AUD) have been linked to alterations in social cognition, including increased egocentric bias. Psychedelics such as psilocybin have been proposed to modulate self-related processing, but their effects on specific socio-cognitive mechanisms remain unclear.

MethodsIn this randomized controlled pilot study, recently detoxified individuals with AUD with persistent depressive symptoms completed a visual perspective-taking task before and after a psilocybin session (25 mg dose vs active placebo 1 mg psilocybin).

ResultsThe 25 mg psilocybin group showed a significant reduction in egocentric bias and egocentric superiority on reaction times, with no effect on altercentric bias nor on accuracy. Between-group comparisons confirmed greater reductions in the high-dose relative to the low-dose group. The high-dose group reported more intense subjective psychedelic experiences, and greater subjective intensity was associated with lower egocentric superiority in accuracy.

ConclusionsThese findings provide preliminary evidence that psilocybin may selectively reduce egocentric interference in individuals with AUD, suggesting a decrease in egocentricity rather than enhanced sensitivity to others. Although replication in larger samples is needed, reduced egocentricity may represent one mechanism through which psilocybin influences social cognition in AUD.

Clinical trial registrationClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06235411, NCT06235411.

Related

  1. Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial
    C. Sayali, E. Weisman, F. S. Barrett
    medRxivPreprintCC BY-NCFull textPsychiatry & mental healthmedRxiv
  2. Intensive cognitive behavioral therapy for obsessive-compulsive disorder: a meta-analysis of randomized controlled trials
    Jianli Zhu, Chunxiao Zhang, Xinpeng Xu +3
    Frontiers in psychiatryPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
  3. Adjunctive Psychobiotic Lactiplantibacillus plantarum PS128 Therapy and Escitalopram in Major Depressive Disorder: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial
    Y. Ji, J. Zhang, J. Mao +5
    medRxivPreprintAll rights reservedFull textPsychiatry & mental healthmedRxiv
  4. Long‐Term Neurodevelopmental Outcome Following Three Randomized Controlled Trials of Choline in Fetal Alcohol Spectrum Disorder (FASD)
    Jeffrey R. Wozniak, Judith K. Eckerle, Blake A. Gimbel +7
    Alcohol, clinical & experimental researchPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.
    P. Tiwari, S. M. Nayak, N. D. Sepeda +9
    medRxivPreprintAll rights reservedFull textPsychiatry & mental healthmedRxiv

Cite

BibTeXRIS
BibTeX
@misc{bukowski2026reduced,
  title = {{Reduced egocentricity after psilocybin in patients with alcohol use disorder: a pilot randomized controlled trial}},
  author = {H. Bukowski and P. de Timary and D. Belahda and N. Igounenc and T. Mura and C. Serrand and A. Luquiens},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.26.26364086},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.26.26364086v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Reduced egocentricity after psilocybin in patients with alcohol use disorder: a pilot randomized controlled trial
AU  - H. Bukowski
AU  - P. de Timary
AU  - D. Belahda
AU  - N. Igounenc
AU  - T. Mura
AU  - C. Serrand
AU  - A. Luquiens
PY  - 2026
DA  - 2026/09/26
PB  - medRxiv
DO  - 10.64898/2026.09.26.26364086
UR  - https://www.medrxiv.org/content/10.64898/2026.09.26.26364086v1
AB  - BackgroundSocial difficulties in alcohol use disorder (AUD) have been linked to alterations in social cognition, including increased egocentric bias. Psychedelics such as psilocybin have been proposed to modulate self-related processing, but their effects on specific socio-cognitive mechanisms remain unclear.  MethodsIn this randomized controlled pilot study, recently detoxified individuals with AUD with persistent depressive symptoms completed a visual perspective-taking task before and after a psilocybin session (25 mg dose vs active placebo 1 mg psilocybin).  ResultsThe 25 mg psilocybin group showed a significant reduction in egocentric bias and egocentric superiority on reaction times, with no effect on altercentric bias nor on accuracy. Between-group comparisons confirmed greater reductions in the high-dose relative to the low-dose group. The high-dose group reported more intense subjective psychedelic experiences, and greater subjective intensity was associated with lower egocentric superiority in accuracy.  ConclusionsThese findings provide preliminary evidence that psilocybin may selectively reduce egocentric interference in individuals with AUD, suggesting a decrease in egocentricity rather than enhanced sensitivity to others. Although replication in larger samples is needed, reduced egocentricity may represent one mechanism through which psilocybin influences social cognition in AUD.  Clinical trial registrationClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06235411, NCT06235411.
ER  -